United Therapeutics jumps on $2B buyback authorization and accelerated repurchase

United Therapeutics (UTHR) is up 7.1% today. Here is some analysis on what might have caused this price movement.

Analysis: The biggest apparent catalyst is a newly authorized $2 billion share repurchase plan, including a large accelerated share repurchase (ASR) that can pull forward buyback impact. The move also comes with recent investor optimism around the company’s pulmonary arterial hypertension (PAH) pipeline following positive phase 3 outcomes for ralinepag.

Details:

The board authorized up to $2.0 billion of share repurchases over the next year, which can mechanically support the stock by reducing share count and signaling confidence.

The company entered into ASR agreements totaling $1.5 billion, with an upfront payment expected on or around March 11, 2026, and an initial delivery of shares expected shortly after execution.

The ASR structure includes both an “uncollared” and a “collared” component, with final settlement dependent on future volume-weighted average prices over the purchase periods.

Separately, the company recently announced its phase 3 ADVANCE OUTCOMES study met its primary endpoint for ralinepag in PAH, and it expects to submit an NDA in the second half of 2026, which may be improving sentiment on longer-term growth.

Sources:

United Therapeutics Investor Relations, SEC

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$UTHR Insider Trading Activity

$UTHR insiders have traded $UTHR stock on the open market 591 times in the past 6 months. Of those trades, 0 have been purchases and 591 have been sales.

Here’s a breakdown of recent trading of $UTHR stock by insiders over the last 6 months:

MICHAEL BENKOWITZ (PRESIDENT AND COO) has made 0 purchases and 194 sales selling 480,815 shares for an estimated $220,758,434.
MARTINE A ROTHBLATT (Chairperson & CEO) has made 0 purchases and 223 sales selling 306,500 shares for an estimated $136,266,749.
JAMES EDGEMOND (CFO AND TREASURER) has made 0 purchases and 74 sales selling 129,517 shares for an estimated $60,347,867.
PAUL A MAHON (EVP & GENERAL COUNSEL) has made 0 purchases and 81 sales selling 110,200 shares for an estimated $51,496,441.
TOMMY G THOMPSON has made 0 purchases and 3 sales selling 7,470 shares for an estimated $3,273,694.
LOUIS W SULLIVAN has made 0 purchases and 2 sales selling 5,950 shares for an estimated $3,047,200.
RAY KURZWEIL sold 4,910 shares for an estimated $2,401,088
CHRISTOPHER CAUSEY has made 0 purchases and 4 sales selling 3,020 shares for an estimated $1,469,817.
JUDY D. OLIAN has made 0 purchases and 2 sales selling 2,000 shares for an estimated $849,677.
CHRISTOPHER PATUSKY sold 1,000 shares for an estimated $495,953
JAN MALCOLM has made 0 purchases and 5 sales selling 900 shares for an estimated $376,741.
NILDA MESA sold 187 shares for an estimated $90,064

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$UTHR Hedge Fund Activity

We have seen 443 institutional investors add shares of $UTHR stock to their portfolio, and 366 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

WELLINGTON MANAGEMENT GROUP LLP added 1,042,711 shares (+74.5%) to their portfolio in Q4 2025, for an estimated $508,060,934
DARWIN GLOBAL MANAGEMENT, LTD. removed 748,550 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $364,730,987
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 609,421 shares (-75.0%) from their portfolio in Q4 2025, for an estimated $296,940,382
AVORO CAPITAL ADVISORS LLC added 583,838 shares (+28.9%) to their portfolio in Q4 2025, for an estimated $284,475,065
CITIGROUP INC removed 367,062 shares (-66.6%) from their portfolio in Q4 2025, for an estimated $178,850,959
JANUS HENDERSON GROUP PLC added 341,383 shares (+75.1%) to their portfolio in Q4 2025, for an estimated $166,338,866
BAILLIE GIFFORD & CO added 323,016 shares (+inf%) to their portfolio in Q4 2025, for an estimated $157,389,546

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$UTHR Government Contracts

We have seen $1,299,812 of award payments to $UTHR over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

TYVASO KITS & CARTRIDGES: $379,307
OPSUMIT 10MG-QTY 4 @ $6,270.03 ADEMPAS 1MG, QTY 1 @ $12,153.05 REMODULIN 5MG/ML INJ 20ML VIAL, QTY 1 @ $6,2...: $49,773
OPSUMIT 10MG-QTY 2 @ 6,270.03 ADEMPAS 1MG, QTY 1 @ 12,153.05 JULY 2025: $37,233
OPSUMIT 10MG-QTY 4 @ 6,270.03 ADEMPAS 1MG, QTY 1 @ 12,153.05 SEPT FY25: $37,233

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.

$UTHR Congressional Stock Trading

Members of Congress have traded $UTHR stock 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $UTHR stock by members of Congress over the last 6 months:

REPRESENTATIVE LISA C. MCCLAIN has traded it 3 times. They made 1 purchase worth up to $15,000 on 10/30 and 2 sales worth up to $30,000 on 10/31, 10/30.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

$UTHR Analyst Ratings

Wall Street analysts have issued reports on $UTHR in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

UBS issued a "Buy" rating on 01/06/2026
HC Wainwright & Co. issued a "Buy" rating on 10/30/2025
RBC Capital issued a "Outperform" rating on 10/30/2025

To track analyst ratings and price targets for $UTHR, check out Quiver Quantitative's $UTHR forecast page.

$UTHR Price Targets

Multiple analysts have issued price targets for $UTHR recently. We have seen 7 analysts offer price targets for $UTHR in the last 6 months, with a median target of $600.0.

Here are some recent targets:

Ashwani Verma from UBS set a target price of $705.0 on 03/05/2026
Lisa Walter from RBC Capital set a target price of $643.0 on 02/26/2026
Andrew S. Fein from HC Wainwright & Co. set a target price of $600.0 on 02/26/2026
Joseph Thome from TD Cowen set a target price of $575.0 on 02/26/2026
Benjamin Burnett from Wells Fargo set a target price of $466.0 on 02/26/2026
Andreas Argyrides from Oppenheimer set a target price of $600.0 on 02/26/2026
Terence Flynn from Morgan Stanley set a target price of $435.0 on 10/10/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.